Urine NT-ProBNP in Neonatal Respiratory Distress

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-12-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is a need for a biochemical marker in addition to clinical condition which will help the physician to understand the clinical progress of the disease.

Urine Nt-proBNP, which does not need any blood sampling and can be collected easily, has not been evaluated for respiratory distress in newborn.

The investigators aim to evaluate the prognostic value of urine NT-proBNP in respiratory diseases in newborns by a controlled trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Predictive Value of Amniotic Fluid pH and Electrolytes on Neonatal Respiratory Disorders

NCT02813954

Respiratory Distress Syndrome Transient Tachypnea of Newborn

COMPLETED

Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants

NCT00799123

Infant, Premature Ductus Arteriosus, Patent Ventricular Function, Left

COMPLETED

Pulse Oximeter Screening in Congenital Heart Disease

NCT02731248

Congenital Heart Disease

UNKNOWN

N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension

NCT00443859

Persistent Pulmonary Hypertension of Newborn

TERMINATED

Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks

NCT00528736

Infant, Premature Ductus Arteriosus, Patent Natriuretic Peptide Brain

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neonatal diseases such as respiratory distress and transient tachypnea of newborn may require high level of intensive care. On the other hand, some minor difficulties in respiration can resolve within hours. Therefore, there is a need for a biochemical marker in addition to clinical condition which will help the physician to understand the clinical progress of the disease.

Serum NT-ProBNP level has been evaluated in transient tachypnea of newborn and found compatible with the clinical progress. Urine NT-proBNP has recently been evaluated in patent ductus arterioses and found compatible with the cardiac progress. However, urine Nt-proBNP, which does not need any blood sampling and can be collected easily, has not been evaluated for respiratory distress in newborn.

The investigators aim to evaluate the prognostic value of urine NT-proBNP in respiratory diseases in newborns by a controlled trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neonatal Respiratory Distress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Respiratory distress group

Newborns with respiratory distress will constitute the study group. All patients will be evaluated by Urine NT-proBNP and echocardiography on postnatal days 1-2 and 5-7.

No interventions assigned to this group

Control Group

Newborns without any respiratory and cardiac diseases will constitute the control group, and will be evaluated by urine Nt-proBNP and echocardiography on postnatal days 1-2 and 5-7.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* study group; newborns who are admitted to the neonatal intensive care unit within first 2 days of life and have transient tachypnea of newborn or respiratory distress syndrome signed informed consent form
* Control Group: Newborns without any respiratory distress

Exclusion Criteria

* any cardiac anomaly sepsis acute renal insufficiency syndromic cases low APGAR score at 5th minute (\<7) lung malformations no informed consent inability in collection of urine

Minimum Eligible Age

1 Day

Maximum Eligible Age

7 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes